However, in the diabetes trials, there appeared to be an attenuation in the treatment effect with increasing age for 3 drug classes (0.07 (95% CI 0.00, 0.13) for sulfonylureas versus SGLT2 inhibitors, 0.09 (95% CI 0.01, 0.17) for DPP-4 inhibitors versus SGLT2 inhibitors, and 0.07 (95% CI 0.04, 0.11) for SGLT2 inhibitors versus placebo). This evidence concerns the gene SLC5A2 and diabetes mellitus.